Karyopharm Therapeutics (KPTI) Other Working Capital Changes (2012 - 2025)

Karyopharm Therapeutics has reported Other Working Capital Changes for 14 years, with the latest figure at $93000.0 in Q4 2025.

• For the quarter ending Q4 2025, Other Working Capital Changes rose 103.72% year-over-year to $93000.0; the trailing twelve-month figure through Dec 2025 stood at -$4.1 million (down 1055.09% YoY), and the FY2025 full-year result was $202864.0, up 147.4% from the prior year.
• Other Working Capital Changes for Q4 2025 stood at $93000.0, up from -$223000.0 in the prior quarter.
• The five-year high for Other Working Capital Changes was $15.6 million in Q1 2022, with the low at -$16.7 million in Q2 2022.
• Historically, Other Working Capital Changes has averaged -$325150.0 across 5 years, with a median of -$692500.0 in 2023.
• The largest YoY upside for Other Working Capital Changes was 5352.53% in 2022 against a maximum downside of 2561.24% in 2022.
• Karyopharm Therapeutics' Other Working Capital Changes stood at -$1.6 million in 2021, then tumbled by 35.49% to -$2.2 million in 2022, then surged by 51.62% to -$1.1 million in 2023, then slumped by 135.5% to -$2.5 million in 2024, then jumped by 103.72% to $93000.0 in 2025.
• The last three Other Working Capital Changes figures came in at $93000.0 (Q4 2025), -$223000.0 (Q3 2025), and -$2.0 million (Q2 2025), per Business Quant data.